When using the FOLFIRI (folinic acid, fluorouracil, irinotecan) regimen combined with bevacizumab, which should be administered first?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

FOLFIRI + Bevacizumab Administration Order

Bevacizumab should be administered FIRST, before the FOLFIRI chemotherapy components, on Day 1 of each cycle.

Standard Administration Sequence

The correct order of administration for FOLFIRI + bevacizumab is:

  1. Bevacizumab 5 mg/kg IV - administered first on Day 1
  2. Irinotecan 180 mg/m² IV - given after bevacizumab on Day 1
  3. Leucovorin 400 mg/m² IV - administered on Day 1
  4. 5-FU 400 mg/m² IV bolus - given on Day 1
  5. 5-FU 2400 mg/m² continuous infusion - over 46-48 hours starting Day 1

This sequence is repeated every 2 weeks 1, 2, 1.

Rationale for Bevacizumab First

Multiple international guidelines consistently specify bevacizumab administration on "day 1" of the FOLFIRI regimen 1, 2, 1, 3. The FDA label for bevacizumab explicitly states it was administered "prior to FOLFOX4 on Day 1" in the E3200 trial, establishing the precedent for anti-VEGF therapy preceding chemotherapy 4.

Practical Administration Details

  • Bevacizumab infusion time: First dose over 90 minutes; if tolerated, subsequent doses can be given over 60 minutes, and eventually over 30 minutes 4
  • Timing: Bevacizumab is given before starting the irinotecan infusion on the same day
  • Cycle frequency: Every 14 days (2-week cycles)
  • Duration: Continue until disease progression or unacceptable toxicity 1, 5

Common Pitfalls to Avoid

Do not reverse the order - giving chemotherapy before bevacizumab contradicts established protocols and may theoretically affect the anti-angiogenic mechanism of action. The anti-VEGF effect is intended to "normalize" tumor vasculature before cytotoxic agents are delivered.

Do not split bevacizumab across multiple days - it must be given as a single infusion on Day 1, not divided between days.

Monitor for infusion reactions during the first bevacizumab administration, as this is when hypersensitivity reactions are most likely to occur 4.

This administration sequence has been validated across multiple phase III trials including WJOG4407G, CRYSTAL, and others, demonstrating both efficacy and safety when bevacizumab precedes FOLFIRI chemotherapy 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.